{"url_path":"/sec/ormp/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ** **Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1176309/0001213900-26-073709-index.html","accession_number":"0001213900-26-073709","cik":"0001176309","ticker":"ORMP","issuer_name":"ORAMED PHARMACEUTICALS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1176309/0001213900-26-073709-index.html","primary_entity_key":"0001176309","primary_entity_name":"ORAMED PHARMACEUTICALS INC."},"word_count":84,"has_tables":true,"body_markdown":"**Item\n9.01** **Financial Statements and Exhibits.**\n\n \n\n**(d) Exhibits**\n\n \n\n**Exhibit No.**\n \n**Description**\n\n3.1\n \n[The Fifth Amended and Restated Bylaws of Oramed Pharmaceuticals, Inc.](ea029652001ex3-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**ORAMED PHARMACEUTICALS INC.**\n\n \n \n \n\n \nBy:\n/s/ Nadav Kidron\n\n \nName:\nNadav Kidron\n\n \nTitle:\nPresident and CEO\n\n \n\nJune 30, 2026\n\n2"}